
Biotherapies & Immunology (CIC-BTi)
Clinical Investigation Center
description
The Clinical Investigation Center in Biotherapy and Immunology has a unique expertise in translational research in immunology. The CIC-BTi offers support to investigators to perform clinical studies - from cognitive to therapeutic studies - in the fields of Biotherapies and Immunology.
The CIC-BTi offers technical, logistic and administrative support to investigators. This includes:
- An overall assessment of the project to establish clinical development plans,
- The design of protocols and associated methodological aspects,
- The design of biological monitoring and when necessary the development of specific tests,
- The GMP production of cell populations, with or without genetic modifications,
- The dealing with all regulatory and administrative aspects.
Previous contributions: The CIC-BTi has contributed to the clinical development of new approaches of T cell manipulations in the field of bone marrow transplantation. We notably reported that the depletion of Treg in donor lymphocytes infusion (DLI) after leukemia relapse post allogeneic hematopoietic stem cell transplantation improves the alloreactivity of the DLI and its therapeutic efficacy. We have also pioneered the clinical use of low-dose IL-2 as a safe Treg inducer in autoimmune and autoinflammatory diseases.
Fields of interest
Regulatory and methodology aspects of biotherapies’ development,
Complex immunomonitoring, Treg and IL-2 clinical trials
Contact info
Address: Hôpital Pitié-Salpêtrière CIC-BTi, Biothérapie, 83 boulevard de l’HôpitalCity: Paris
Postal code: 75651
Telephone: +33 1 42 17 74 73
Fax: +33 1 42 17 74 62
Email: michelle.rosenzwajg@sorbonne-universite.fr
Website: http://www.dhu-i2b.fr/en/Member/CIC-BTi
Top Publications
- Hulot JS, Salem JE, Redheuil A, Collet JP, Varnous S, Jourdain P, Logeart D, Gandjbakhch E, Bernard C, Hatem SN, Isnard R, Cluzel P, Le Feuvre C, Leprince P, Hammoudi N, Lemoine FM, Klatzmann D, Vicaut E, Komajda M, Montalescot G, Lompré AM, Hajjar RJ; AG
Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial
Eur J Heart Fail 2017, 19(11):1534-1541 - Maury S, Rosenzwajg M, Redjoul R, Marcais A, Xhaard A, Cherai M, Cabanne L, Churlaud G, Suarez F, Socié G, Grégoire L, Debbache K, Bernard C, Beaumont JL, Azar N, Boyer O, Roudot-Thoraval F, Cohen JL, Cordonnier C, Lemoine FM, Klatzmann D
Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study
Leukemia 2014, 28(12):2406-10
Cognitive Clinical Investigations
- Terrier B, Joly F, Vazquez T, Benech P, Rosenzwajg M, Carpentier W, Garrido M, Ghillani‐Dalbin P, Klatzmann D, Cacoub P*, Saadoun D
Expansion of functionally anergic CD21‐/low marginal zone‐like B cell clones in hepatitis C virus infection‐related autoimmunity
J Immunol. 187(12), 6550-6563 (2011) - Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D, Tran TA, Bodaghi B, Musset L, Soumelis V, Klatzmann D, Cacoub P, Saadoun D
Critical role of IL‐21 in modulating T(H)17 and regulatory T cells in Behçet disease
J Allergy Clin Immunol. 128(3), 655‐664 (2011)